These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30988472)

  • 1. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.
    Hu CW; Qiu Y; Ligeralde A; Raybon AY; Yoo SY; Coombes KR; Qutub AA; Kornblau SM
    Nat Biomed Eng; 2019 Nov; 3(11):889-901. PubMed ID: 30988472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
    Balkhi MY; Trivedi AK; Geletu M; Christopeit M; Bohlander SK; Behre HM; Behre G
    Oncogene; 2006 Nov; 25(53):7041-58. PubMed ID: 16732326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.
    Sjøholt G; Anensen N; Wergeland L; Mc Cormack E; Bruserud Ø; Gjertsen BT
    Curr Drug Targets; 2005 Sep; 6(6):631-46. PubMed ID: 16178797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
    van Dijk AD; de Bont ESJM; Kornblau SM
    Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
    [No Abstract]   [Full Text] [Related]  

  • 5. A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development.
    Strassberger V; Gutbrodt KL; Krall N; Roesli C; Takizawa H; Manz MG; Fugmann T; Neri D
    J Proteomics; 2014 Mar; 99():138-51. PubMed ID: 24487095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative proteome analysis of bone marrow interstitial fluid and serum reveals candidate signature for acute myeloid leukemia.
    Jajula S; Naik V; Kalita B; Yanamandra U; Sharma S; Chatterjee T; Bhanuse S; Bhavsar PP; Taunk K; Rapole S
    J Proteomics; 2024 Jul; 303():105224. PubMed ID: 38866132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic hallmarks in AML.
    Clarke MA; Fisher J
    Nat Biomed Eng; 2019 Nov; 3(11):847-849. PubMed ID: 31705121
    [No Abstract]   [Full Text] [Related]  

  • 8. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.
    Aasebø E; Vaudel M; Mjaavatten O; Gausdal G; Van der Burgh A; Gjertsen BT; Døskeland SO; Bruserud O; Berven FS; Selheim F
    Proteomics; 2014 Sep; 14(17-18):1971-6. PubMed ID: 25044641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of protein profile classification model and screening of proteomic signature of acute leukemia.
    Xu Y; Zhuo J; Duan Y; Shi B; Chen X; Zhang X; Xiao L; Lou J; Huang R; Zhang Q; Du X; Li M; Wang D; Shi D
    Int J Clin Exp Pathol; 2014; 7(9):5569-81. PubMed ID: 25337199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients.
    Aasebø E; Forthun RB; Berven F; Selheim F; Hernandez-Valladares M
    Curr Pharm Biotechnol; 2016; 17(1):52-70. PubMed ID: 26306748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic and proteomic analysis of mouse radiation-induced acute myeloid leukaemia (AML).
    Badie C; Blachowicz A; Barjaktarovic Z; Finnon R; Michaux A; Sarioglu H; Brown N; Manning G; Benotmane MA; Tapio S; Polanska J; Bouffler SD
    Oncotarget; 2016 Jun; 7(26):40461-40480. PubMed ID: 27250028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.
    Hernandez-Valladares M; Bruserud Ø; Selheim F
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of IKZF1 genetic mutations as new molecular subtypes in acute myeloid leukaemia.
    Wang Y; Cheng W; Zhang Y; Zhang Y; Sun T; Zhu Y; Yin W; Zhang J; Li J; Shen Y
    Clin Transl Med; 2023 Jun; 13(6):e1309. PubMed ID: 37345307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows.
    Aasebø E; Mjaavatten O; Vaudel M; Farag Y; Selheim F; Berven F; Bruserud Ø; Hernandez-Valladares M
    J Proteomics; 2016 Aug; 145():214-225. PubMed ID: 27107777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional proteomic profiling of AML predicts response and survival.
    Kornblau SM; Tibes R; Qiu YH; Chen W; Kantarjian HM; Andreeff M; Coombes KR; Mills GB
    Blood; 2009 Jan; 113(1):154-64. PubMed ID: 18840713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.
    Alanazi B; Munje CR; Rastogi N; Williamson AJK; Taylor S; Hole PS; Hodges M; Doyle M; Baker S; Gilkes AF; Knapper S; Pierce A; Whetton AD; Darley RL; Tonks A
    Leukemia; 2020 Feb; 34(2):427-440. PubMed ID: 31611628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome.
    Wangen R; Aasebø E; Trentani A; Døskeland SO; Bruserud Ø; Selheim F; Hernandez-Valladares M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29351208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative proteomics approach identifies ETV6 and IKZF1 as new regulators of an ERG-driven transcriptional network.
    Unnikrishnan A; Guan YF; Huang Y; Beck D; Thoms JA; Peirs S; Knezevic K; Ma S; de Walle IV; de Jong I; Ali Z; Zhong L; Raftery MJ; Taghon T; Larsson J; MacKenzie KL; Van Vlierberghe P; Wong JW; Pimanda JE
    Nucleic Acids Res; 2016 Dec; 44(22):10644-10661. PubMed ID: 27604872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.
    Forthun RB; Aasebø E; Rasinger JD; Bedringaas SL; Berven F; Selheim F; Bruserud Ø; Gjertsen BT
    J Proteomics; 2018 Feb; 173():32-41. PubMed ID: 29175091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.